For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

GHRP-2 vs Mod-GRF(1-29)

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GHRP-2Mod-GRF(1-29)
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asGrowth Hormone Releasing Peptide-2, Pralmorelin, KP 102Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog
EvidencePreclinical onlyResearch-stage
Dosing range100mcg–300mcg mcg, 1–3 times daily, on an empty stomach100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking)
AdministrationSubcutaneous injection, Intramuscular injectionSubcutaneous injection, Intramuscular injection
Key side effectsIncreased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritationWater retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site
Cited sources3 references2 references

Key differences

  • Evidence level differs: GHRP-2 is preclinical only, while Mod-GRF(1-29) is research-stage.
  • Frequency: GHRP-2 is typically 1–3 times daily, on an empty stomach; Mod-GRF(1-29) is 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking).
  • Research depth: this profile cites 3 sources for GHRP-2 vs 2 for Mod-GRF(1-29).

How each works

GHRP-2

GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.

Mod-GRF(1-29)

Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.

Read the full GHRP-2 profileRead the full Mod-GRF(1-29) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.